SCHEMBL1474546

SCHEMBL1474546

O=C(NCCCn1ccnc1)c1cc(-c2cccc(C(F)(F)F)c2)on1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.76
LMNA P02545 6/20 0.75
NPC1 O15118 2/20 0.75
HTT P42858 1/20 0.75
SMN1; SMN2 Q16637 1/20 0.75
HIF1A Q16665 1/20 0.75
ALDH1A1 P00352 3/20 0.67
GAA P10253 1/20 0.67
MAPK1 P28482 2/20 0.65
KDM4E B2RXH2 5/20 0.64
NFKB1 P19838 1/20 0.64
NFKB2 Q00653 1/20 0.64
RELA Q04206 1/20 0.64
GLA P06280 1/20 0.60
HSD17B10 Q99714 1/20 0.60
HDAC4 P56524 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
MAPT P10636 1/20 0.52
FAAH O00519 1/20 0.52
CYP1A2 P05177 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1474847 0.90 LMNA (0.77) RAB9ALMNANPC1HTTSMN1; SMN2
SCHEMBL1178090 0.88 RAB9A (0.80) RAB9ALMNANPC1HTTSMN1; SMN2
SCHEMBL1474942 0.87 RAB9A (1.00) RAB9ALMNANPC1HTTSMN1; SMN2
SCHEMBL1179277 0.86 LMNA (1.00) RAB9ALMNANPC1HTTSMN1; SMN2
SCHEMBL15190444 0.86 RAB9A (0.56) RAB9ALMNANPC1HTTSMN1; SMN2
SCHEMBL1179157 0.86 RAB9A (0.80) RAB9ALMNANPC1HTTSMN1; SMN2
SCHEMBL1178087 0.86 RAB9A (0.80) RAB9ALMNANPC1HTTSMN1; SMN2
SCHEMBL30087234 0.84 LMNA (0.83) RAB9ALMNANPC1HTTSMN1; SMN2
SCHEMBL1476364 0.84 LMNA (0.83) RAB9ALMNANPC1HTTSMN1; SMN2
SCHEMBL1178656 0.83 LMNA (1.00) RAB9ALMNANPC1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 RAB9A 2013/4885LMNA 2934/4885NPC1 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.